Comparative studies for ciprofloxacin hydrochloride pre-formed gels and thermally triggered (in situ) gels: In vitro and in vivo appraisal using a bacterial keratitis model in rabbits

Pharmaceutical Development and Technology

Volumn 20, Issue 4, 2015, Pages 410-416

  Abdelkader, Hamdy ^a   Mansour, Heba F ^a  

^a Minia University   (Egypt)

Author keywords

In situ gel; Keratitis; Methylcellulose; Ocular delivery; Pre formed gel; Viscosity

Indexed keywords

CARBOXYMETHYLCELLULOSE; CIPROFLOXACIN; ETHYL CELLULOSE; METHYLCELLULOSE; POLOXAMER; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; GEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL KERATITIS; CELL LOSS; CELL VACUOLE; COMPARATIVE EFFECTIVENESS; CORNEA STROMA; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; ENVIRONMENTAL TEMPERATURE; EYE TOXICITY; FEMALE; FLOW KINETICS; GELATION; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; OSMOLALITY; PH; PIGMENTED RABBIT; PRIORITY JOURNAL; QUALITY CONTROL; STAPHYLOCOCCUS AUREUS; SURFACE TENSION; THERMAL ANALYSIS; VISCOSITY; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; COMPLICATION; CORNEA; DELAYED RELEASE FORMULATION; DRUG EFFECTS; GEL; KERATITIS; MICROBIOLOGY; RABBIT; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBOXYMETHYLCELLULOSE SODIUM; CIPROFLOXACIN; CORNEA; DELAYED-ACTION PREPARATIONS; FEMALE; GELS; KERATITIS; MALE; METHYLCELLULOSE; POLOXAMER; RABBITS; RHEOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VISCOSITY;

EID: 84929407659     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.871034     Document Type: Article

References (25)

1. McLeod S. Infectious keratitis. In: Yanoff M, Duker J, eds. Ophthalmology. St. Louis: Mosby; 2004.
2. Thomas P, Geraldine P. Infectious keratitis. Curr Opin Infect Dis 2007;20:129-141.
3. Armstrong RA. The microbiology of the eye. Ophthal Physiol Opt 2000;20:429-441.
4. Egger SF, Ruckhofer J, Alzner E, et al. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthal Res 2001;33:117-120.
5. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol 2004;49:S79-S83.
6. Sweetman S. Matindale: The complete drug reference. London: Pharmaceutical Press; 2009.
7. Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J Pharm Sci 1976;65:1295-1301.
8. Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine. J Pharm Sci 1977;66:1222-1228.
9. Middleton DL, Leung SS, Robinson JR. Bioadhesive drug delivery systems. Boca Raton (FL): CRC Press; 1990.
10. Wilhelmus KR, Abshire RL. Corneal ciprofloxacin precipitation during bacterial keratitis. Am J Ophthalmol 2003;136:1032-1037.
11. Budai M, Szabó Z, Zimmer A, et al. Studies on molecular interactions between nalidixic acid and liposomes. Int J Pharm 2004;279:67-79.
12. Lang JC, Roehrs RE, Rodeheaver DP, et al. Design and evaluation of ophthalmic pharmaceutical products. In: Banker GS, Rhodes CT, eds. Modern phatmaceutics. New York: Marcel Dekker; 2002.
13. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Del Rev 2005;57:1595-1639.
14. Burgalassi S, Chetoni P, Panichi L, et al. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther 2000;16:497-509.
15. Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990;74:477-480.
16. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Rel 2007;122: 119-134.
17. Felt O, Baeyens V, Zignani M, et al. Mucosal drug delivery-ocular. Encyclopedia of controlled drug delivery. Geneva: University of Geneva; 1999.
18. Zagon IS, Klocek MA, Sassani JW, et al. Corneal safety of topically applied naltrexone. J Ocul Pharmacol Ther 2006;22:377-387.
19. GraphPad InStat version 3.00, GraphPad Software, Inc., San Diego, CA, USA, 1995. Available from: www.graphpad.com.
20. Dillen K, Vandervoort J, van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/ PLGA nanoparticles. Int J Pharm 2006;314:72-82.
21. Sinko PJ. Pharmaceutical polymers. In: Troy DB, ed. Martin's physical pharmacy and pharmaceutical sciences. Philadelphia (PA): Lippincott Williams & Wilkins; 2011.
22. Burgess DL. Drug dissolution: method development. Auckland: The Australian & New Zealand Chapters of the Controlled Release Society: In Vitro Drug Release and Dissolution Testing Workshop; 2010.
23. Harbell JW, Raabe HA, Evans MG, Curren RD. Histopathology associated with opacity and permeability changes in bovine corneas in vitro. The Toxicologist 1999;48:336-337.
24. Harbell JW, Mun G, Curren RD. Application of histological evaluation to enhance the bovine opacity and permeability (BCOP) assay. The 45th Annual Society of Toxicology Meeting, San Diego, CA, USA; 2006.
25. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 2002;54:37-51.